GlassScriptPhysician profile
Robin Eileen Boliver-Campbell
NPI 1003096033
$8,639.19
in general payments reported to CMS, 2019-2025
33 companies · $2,483 in 2025
The $2,483 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2022: $627 · 2023: $2,221 · 2024: $3,124 · 2025: $2,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,667 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,666.93 |
| Education | $160.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,875.38 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $959.44 | 2023-2025 | Evenity, Repatha, Prolia |
| Novo Nordisk INC | $878.92 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $719.24 | 2022-2025 | Mounjaro, Kisunla, Jardiance |
| Abbvie INC. | $567.28 | 2023-2025 | Vraylar |
| Gilead Sciences, INC. | $530.78 | 2024-2025 | Yeztugo, Biktarvy, Epclusa |
| Otsuka America Pharmaceutical, INC. | $471.08 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $415.51 | 2023-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $323.03 | 2023-2025 | |
| Abbott Laboratories | $244.63 | 2019-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $214.57 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.48 | 2022-2025 | Jardiance |
| Pfizer INC. | $155.90 | 2023-2025 | |
| Glaxosmithkline, LLC. | $143.40 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Globus Medical, INC. | $133.25 | 2024 | Excelsius3d Imaging System |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $119.16 | 2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $113.68 | 2023-2025 | Spravato |
| Viiv Healthcare Company | $108.99 | 2024 | |
| Idorsia Pharmaceuticals US INC | $84.45 | 2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.40 | 2025 | Caplyta |
| Millicent US INC | $45.15 | 2025 | Femlyv, Intrarosa, Femring |
| Vanda Pharmaceuticals INC. | $42.14 | 2023 | Hetlioz |
| Verity Pharmaceuticals INC. | $40.83 | 2025 | Tlando |
| Corcept Therapeutics | $30.31 | 2025 | Korlym |
| Kyowa Kirin, INC. | $24.74 | 2025 | |
| Organon LLC | $23.64 | 2025 | Nexplanon |
| Cleerly, INC. | $23.18 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Edwards Lifesciences Corporation | $20.84 | 2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $20.63 | 2025 | Inceptiv |
| Azurity Pharmaceuticals, INC. | $19.74 | 2025 | Azmiro |
| Insulet Corporation | $18.92 | 2025 | Omnipod |
| Paratek Pharmaceuticals, INC. | $16.78 | 2025 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $16.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Boliver-Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.